Quick answer: latest quarter results, by ticker or company name

Reported Q: Q2 2025 Rev YoY: -7.9% EPS YoY: +63.9% Move: +4.97%

Previous: Q1 2025 Next: Q3 2025

AngioDynamics Inc

ANGO

$10.56 4.97%

Exchange NASDAQ Sector Healthcare Industry Medical Instruments Supplies

Q2 2025

Published: Jan 8, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for ANGO

Reported

Report Date

Jan 8, 2025

Quarter Q2 2025

Revenue

72.85M

YoY: -7.9%

EPS

-0.26

YoY: +63.9%

Market Move

+4.97%

Previous quarter: Q1 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $72.85M down 7.9% year-over-year
EPS of $-0.26 increased by 63.9% from previous year
Gross margin of 54.8%
Net income of -10.74M
""Total worldwide revenue was $73 million, representing growth of approximately 9% year-over-year." - Jim Clemmer, CEO" - Jim Clemmer

ANGO

AngioDynamics Inc

Period Q2 2025

Currency USD

Report Type Quarterly Earnings

Generated Feb 9, 2026

Executive Summary

AngioDynamics Inc (ANGO) reported its fiscal Q2 2025 results with total revenue of $73 million, marking a 9.2% growth year-over-year, primarily driven by strong performance within its MedTech segment, which saw a 25% increase in revenue. Despite posting a net income loss of $10.7 million for the quarter, management has expressed optimism regarding the companyâ€™s trajectory towards profitability with positive adjusted EBITDA of $3.1 million and expectations of sustained profitability moving forward. Improved performance metrics reinforce the companyâ€™s strategic pivot towards high-growth MedTech markets, whereby adjusted EBITDA is projected to be positive for the full year, showcasing effective cost management and revenue growth strategies.

Key Performance Indicators

Revenue

Decreasing

72.85M

QoQ: 7.93% | YoY: -7.88%

Gross Profit

Decreasing

39.91M

54.78% margin

QoQ: 8.66% | YoY: -0.88%

Operating Income

Increasing

-2.51M

QoQ: 80.85% | YoY: 80.88%

Net Income

Increasing

-10.74M

QoQ: 16.10% | YoY: 63.03%

EPS

Increasing

-0.26

QoQ: 16.13% | YoY: 63.89%

Revenue Trend

Margin Analysis

Financial Highlights

##### Key Financial Metrics:
- Total Revenue: $73 million (YoY +9.2%)
- Gross Profit: $39.9 million (YoY -0.9%)
- Operating Income: -$2.5 million (YoY Improve +80.8%)
- Net Income: -$10.7 million (YoY Improve +63.0% from losses)
- Adjusted EBITDA: $3.1 million
- Cash Position: $54.1 million at period end

##### Performance Ratios:
- Gross Margin: 54.7%
- Operating Margin: -3.4%
- Net Margin: -14.7%
- Current Ratio: 1.98
- Quick Ratio: 1.23
- Debt Ratio: 1.7% (Debt-Free Status)

Overall, the revenue performance depicts a solid momentum in recovery primarily attributed to the MedTech segment's diversification and market expansion initiatives.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	72.85M	-7.88%	7.93%
Gross Profit	39.91M	-0.88%	8.66%
Operating Income	-2.51M	80.88%	80.85%
Net Income	-10.74M	63.03%	16.10%
EPS	-0.26	63.89%	16.13%

Key Financial Ratios

Gross Profit Margin

Good

54.80%

Gross profit margin is healthy and competitive within industry standards

Operating Profit Margin

Weak

-0.03%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

-0.15%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

-0.04%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

-0.06%

Return on equity suggests inefficient capital allocation

Current Ratio

Healthy

1.98

Current ratio shows adequate liquidity to meet short-term obligations

Debt to Equity

Conservative

0.03

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Negative

-6.60x

Negative earnings make P/E ratio not meaningful

Price to Book

Fair Value

1.52x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2026	79.43	-0.15	+17.7%	View
Q1 2026	75.71	-0.26	+6.7%	View
Q3 2025	72.00	-0.11	-4.2%	View
Q2 2025	72.85	-0.26	-7.9%	View
Q1 2025	67.49	-0.31	-14.2%	View

AngioDynamics Inc (ANGO) Q2 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More ANGO Quarterly Reports

ANGO

ANGO

ANGO

ANGO

Q2 2025 Reports in Healthcare Sector

HAE

Related Financial Data

Sector Analysis: Healthcare

ANGO Full Profile

ANGO Financial Statements

Earnings Calendar